Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma

Alan J. Kraker, Craig Andrew Mizzen, Brian G. Hartl, Johnson Miin, C. David Allis, Ronald L. Merriman

Research output: Contribution to journalArticle

Abstract

CI-994 or N-acetyldinaline [4-(acetylamino)-N-(2-aminophenyl) benzamide] is an antitumor cytostatic agent currently undergoing clinical trial. Although several changes in cellular metabolism induced by the drug have been characterized, the primary molecular mechanism of its antitumor activity has been previously unknown. Here, we show that CI-994 is a histone deacetylase (HDAC) inhibitor that causes histone hyperacetylation in living cells. In assays of isolated enzymes, CI-994 inhibited HDAC-1 and HDAC-2 in a concentration-dependent fashion but had no effect on the activity of the prototypical histone acetyltransferase GCN5. Acetylated histone H3-specific Western blots were used to monitor histone acetylation in HCT-8 colon carcinoma cells treated with CI-994 in vitro. CI-994 induced hyperacetylation of H3 in a timeand dose-dependent fashion. H3 hyperacetylation was detectable as early as 30 min after the addition of CI-994 to cells. These data demonstrate that inhibition of HDAC is an early event in cells treated with CI-994 and suggest that this inhibition is mechanistically related to the antitumor activity of this compound.

Original languageEnglish (US)
Pages (from-to)401-408
Number of pages8
JournalMolecular Cancer Therapeutics
Volume2
Issue number4
StatePublished - Apr 1 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Kraker, A. J., Mizzen, C. A., Hartl, B. G., Miin, J., Allis, C. D., & Merriman, R. L. (2003). Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Molecular Cancer Therapeutics, 2(4), 401-408.